Abstract 2708
Background
Docetaxel and cabazitaxel prolong survival in mCRPC however less is known about their utilisation patterns and impact in the setting of androgen receptor-targeted agents (ARTAs; abiraterone and enzalutamide). We evaluated whether receipt of chemotherapy is associated with better survival in pts with mCRPC.
Methods
Optum® de-identified Electronic Health Record dataset was used to identify pts with mCRPC who received first-line docetaxel or an ARTA between 01/05/11 and 30/09/17, followed by chemotherapy (docetaxel, cabazitaxel) and/or ARTA. Pts receiving chemotherapy in ≥ 1 line of treatment (any chemotherapy) vs pts not receiving chemotherapy in any treatment line (no chemotherapy) were assessed. Overall survival (OS) was calculated from start of first-line mCRPC treatment until death from any cause.
Results
In total, 1,961 pts were identified (any chemotherapy 823; no chemotherapy 1,138). Some baseline characteristics differed numerically between treatment groups. Chemotherapy-treated pts had a younger median age, greater pain medication utilisation, more metastases (including liver and lung) and a higher comorbidity score, compared with pts not receiving chemotherapy (Table). For any vs no chemotherapy, median OS was 25.4 months (95% CI 22.3–27.4 ) vs 22.4 months (95% CI 20.4–25.0 ) and the respective 12- and 24-month survival rates were 77.2% (95% CI 0.74–0.80) vs 71.3% (95% CI 0.68–0.74) and 52.1% (95% CI 0.48–0.56) vs 47.4% (95% CI 0.44–0.51).Table:
856P
Any chemotherapy N = 823 | No chemotherapy N = 1138 | |
---|---|---|
Median age at prostate cancer diagnosis, years (range) | 63.2 (25–87) | 68.0 (22–89) |
Median age at first-line mCRPC treatment, years (range) | 70.5 (43–88) | 77.5 (48–90) |
Charlson comorbidity index, median (range) | N = 819 9 (2–18) | N = 1122 8 (0–18) |
Opioid analgesic use at first-line mCRPC treatment, n (%) | 532 (64.6) | 619 (54.4) |
Number of metastases at first-line mCRPC treatment, median (range) | N = 762 7 (1–26) | N = 1032 6 (1–36) |
Visceral metastases, n (%) Liver lung lymph missing | N = 762 57 (7.5) 63 (8.3) 115 (15.1) 61 (3.1) | N = 1032 38 (3.7) 51 (4.9) 111 (10.8) 106 (4.4) |
Conclusions
In this real-world data analysis, less than half of pts with mCRPC received chemotherapy. Pts receiving chemotherapy were younger but had more reported metastases and comorbidities, and were more frequently prescribed pain medication. Despite these higher risk disease characteristics, median OS was observed to be higher in pts receiving any vs no chemotherapy.
Clinical trial identification
Editorial acknowledgement
Danielle Lindley and Mark Cockerill, Meditech Media.
Legal entity responsible for the study
The authors.
Funding
Sanofi.
Disclosure
A.K. Morgans: Honoraria (self): Astellas; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (self): Bayer; Honoraria (self): Sanofi; Honoraria (self): Janssen; Honoraria (self): Genentech. H.A. Divan: Full / Part-time employment: Sanofi. A.J. Birtle: Advisory / Consultancy: Janssen; Advisory / Consultancy, Non-remunerated activity/ies: Astellas; Advisory / Consultancy, Non-remunerated activity/ies: Bayer; Advisory / Consultancy: Sanofi Genzyme; Advisory / Consultancy, Non-remunerated activity/ies: Roche; Advisory / Consultancy: MSD; Non-remunerated activity/ies: Novartis; Non-remunerated activity/ies: Ferring; Non-remunerated activity/ies: Sanofi. T. Dorff: Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy: Janssen; Speaker Bureau / Expert testimony: Exelixis; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Eisai; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Prometheus; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Roche. A. Ozatilgan: Full / Part-time employment: Sanofi. J.N. Graff: Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Sanofi; Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Merck; Advisory / Consultancy, Research grant / Funding (self): Astellas/Pfizer; Research grant / Funding (self), Investigator initiated trial funding: Janssen; Honoraria (self), Expert witness testimony: Bergman Draper Oslund; Honoraria (self), CME activity: i3 Health.
Resources from the same session
4096 - Patient experience and use of an intervention combining nurse-led telephone and technologies for the monitoring of oral cancer medication
Presenter: Marie Ferrua
Session: Poster Display session 3
Resources:
Abstract
6042 - Harnessing nurse leadership to implement a project for electronic scheduling of chemotherapy
Presenter: Emma Masters
Session: Poster Display session 3
Resources:
Abstract
3123 - Turkish Cancer Patients’ Preference for Information and Communication Technologies
Presenter: Esra ildes
Session: Poster Display session 3
Resources:
Abstract
6062 - Unmet Needs in Oncology Research related to radiological response evaluation: a multi-center survey in three European countries
Presenter: Sophie Nisse Durgeat
Session: Poster Display session 3
Resources:
Abstract
6109 - A program implementation to facilitate intraoperative brachytherapy between hospitals
Presenter: Marc Garcia Casellas
Session: Poster Display session 3
Resources:
Abstract
1772 - Using Mobile-Based Health Care Applications Outcomes: Mini Systematic Review
Presenter: Aydanur Aydin
Session: Poster Display session 3
Resources:
Abstract
2792 - Evaluation of an education program for cancer patients receiving chemotherapy
Presenter: Iraqi Amina
Session: Poster Display session 3
Resources:
Abstract
3715 - iGestSaúde: Application for self-management of symptoms during chemotherapy treatment
Presenter: Bruno Magalhaes
Session: Poster Display session 3
Resources:
Abstract
3854 - Palliative care requirements of cancer patients and investigation of knowledge and expectations related to palliative care of the patients and their families
Presenter: Ozlem Topkaya
Session: Poster Display session 3
Resources:
Abstract
4997 - Hospice care, what to expect? An exploration of the expectation of future hospice patients
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract